Kiniksa Pharmaceuticals International, plc Increase (Decrease) in Deferred Revenue
Kiniksa Pharmaceuticals International, plc (KNSA) reported Increase (Decrease) in Deferred Revenue of $19.55 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-02-24
- Kiniksa Pharmaceuticals International, plc increase (decrease) in deferred revenue for the quarter ending 2024-12-31 was $20.00M.
- Kiniksa Pharmaceuticals International, plc increase (decrease) in deferred revenue for the quarter ending 2024-09-30 was -$1.00K.
- Kiniksa Pharmaceuticals International, plc increase (decrease) in deferred revenue for the quarter ending 2024-06-30 was -$155.00K.
- Kiniksa Pharmaceuticals International, plc increase (decrease) in deferred revenue for the quarter ending 2024-03-31 was -$294.00K, a 104.42% decline year-over-year.
- Kiniksa Pharmaceuticals International, plc increase (decrease) in deferred revenue for fiscal 2024 was $19.55M, a 7390.42% increase from fiscal 2023.
- Kiniksa Pharmaceuticals International, plc increase (decrease) in deferred revenue for fiscal 2023 was $261.00K, a 97.82% decline from fiscal 2022.
- Kiniksa Pharmaceuticals International, plc increase (decrease) in deferred revenue for fiscal 2022 was $12.00M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2024-12-31 | $20.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $20.00M derived: sum of 2 quarters · filed 2026-02-24 | $19.84M derived: sum of 3 quarters · filed 2026-02-24 | $19.55M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$156.00K derived: sum of 2 quarters · filed 2025-10-28 | -$450.00K 10-Q · filed 2025-10-28 | -$2.63M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$155.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | -$449.00K 10-Q · filed 2025-07-29 | -$2.62M derived: sum of 3 quarters · filed 2026-02-24 | -$4.87M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$294.00K 10-Q · filed 2025-04-29 | -$2.47M derived: sum of 2 quarters · filed 2026-02-24 | -$4.71M derived: sum of 3 quarters · filed 2026-02-24 | -$6.69M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | -$2.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$4.42M derived: sum of 2 quarters · filed 2026-02-24 | -$6.40M derived: sum of 3 quarters · filed 2026-02-24 | $261.00K 10-K · filed 2026-02-24 |
| 2023-09-30 | -$2.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | -$4.22M derived: sum of 2 quarters · filed 2024-10-29 | $2.44M 10-Q · filed 2024-10-29 | -$11.85M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$1.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-25 | $4.68M 10-Q · filed 2024-07-25 | -$9.61M derived: sum of 3 quarters · filed 2025-02-25 | $4.68M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $6.66M 10-Q · filed 2024-04-25 | -$7.63M derived: sum of 2 quarters · filed 2025-02-25 | $6.66M derived: sum of 3 quarters · filed 2025-02-25 | $6.66M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$14.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $0.00 derived: sum of 2 quarters · filed 2025-02-25 | $0.00 derived: sum of 3 quarters · filed 2025-02-25 | $12.00M 10-K · filed 2025-02-25 |
| 2022-09-30 | $14.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $14.29M derived: sum of 2 quarters · filed 2023-11-02 | $26.29M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $12.00M 10-Q · filed 2023-08-01 | ||
| 2022-03-31 | $12.00M 10-Q · filed 2023-05-04 |